Pfizer Halts Ranbaxy's Diflucan Generic With Court Ruling

Law360, New York (March 12, 2004, 12:00 AM EST) -- The U.S. District Court in Washington, D.C. has upheld Pfizer’s six-month pediatric exclusivity for its top selling anti-fungal medicine, Diflucan.

The court’s decision keeps a generic version by Indian drugmaker Ranbaxy Laboratories Ltd. off the market until July 29.

The ruling came in response to a suit filed by the generic manufacturer Ranbaxy contending that its generic version of Diflucan was not subject to the exclusivity period for Pfizer's product.

A previous lawsuit brought by Pfizer against Ranbaxy for infringement of its patent for Diflucan was...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.